onemocnění. Kombinace farmakologické léčby, změn životního stylu a preventivních strategií může výrazně snížit riziko srdečních a cévních komplikací. Reference 1. Ference, B. A., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. European Heart Journal, 38(32), 2459-2472. 2. Gordon, D. J., & Rifkind, B. M. (1989). Highdensity lipoprotein—the clinical implications of recent studies. New England Journal of Medicine, 321(19), 1311-1316. 3. Robinson, J. G., et al. (2016). Non–highdensity lipoprotein cholesterol and apolipoprotein B predict cardiovascular events among patients with low low-density lipoprotein cholesterol. Journal of the American Heart Association, 5(3), e002771. 4. Libby, P. (2002). Inflammation in atherosclerosis. Nature, 420(6917), 868-874. 5. Ridker, P. M. (2016). From C-reactive protein to interleukin-6 to interleukin-1. Circulation Research, 118(1), 145-156. 6. National Cholesterol Education Program (NCEP). (2002). Third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation, 106(25), 3143-3421. 7. Sniderman, A. D., et al. Apolipoprotein B versus non-HDL cholesterol: diagnosis and treatment of cardiovascular risk. Circulation. 2011;124(2):192–197. 8. Ference, B. A., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. Eur Heart J. 2017;38(32):2459–2472. 9. Krauss, R. M. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21(4):305–311. 10. Sniderman, A. D., et al. (2019). Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy. The Lancet, 381(9865), 64-76. 11. Sturm, A. C., et al. (2018). Clinical genetic testing for familial hypercholesterolemia. Journal of the American College of Cardiology, 72(6), 662-680. 12. Khera, A. V., et al. (2016). Genetic risk, adherence to a healthy lifestyle, and coronary disease. New England Journal of Medicine, 375(24), 2349-2358. 13. Istvan, E. S., & Deisenhofer, J. (2001). Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 292(5519), 1160-1164. 14. Cholesterol Treatment Trialists' (CTT) Collaborators. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol. The Lancet, 376(9753), 1670-1681. 15. Seidah, N. G., & Prat, A. (2012). The biology and therapeutic targeting of the proprotein convertases. Nature Reviews Drug Discovery, 11(5), 367-383. 16. Sabatine, M. S., et al. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine, 376(18), 1713-1722. 17. Cannon, C. P., et al. (2015). Ezetimibe added to statin therapy after acute coronary syndromes. New Eng-land Journal of Medicine, 372(25), 23872397. Kapitola: Současná věda a cholesterol dnes 800 182 572 7:30-16:30 (Pá: do 14:00) Vyhlídka 39, 63800 Brno, Česká republika Tel: +420 545 222 863 Fax: +420 545 222 011 www.vitaminy-mineraly.cz Strana 31
RkJQdWJsaXNoZXIy Nzg5MDg=